For purposes of this subchapter, the following definitions shall apply unless the context clearly indicates or requires a different meaning:
PRODUCT CONTAINING A SYNTHETIC ALTERNATIVE DRUG. Any product containing a synthetic cannabinoid, stimulant or psychedelic/hallucinogen, as those terms are defined herein such as, but not limited to, the examples of brand names or identifiers listed on Exhibit "A" attached to Ordinance No. 2011-62 and incorporated herein by reference.
SYNTHETIC CANNABINOID. Any laboratory-created compound that functions similar to the active ingredient in marijuana, tetrahydrocannabinol (THC), including, but not limited to, any quantity of a natural or synthetic material, compound, mixture, preparation, substance and their analog (including isomers, esters, ethers, salts, and salts of isomers) containing a cannabinoid receptor agonist, such as:
(1) JWH-007 (l-pentyl-2-methyl-3- (l-naphthoyl)indole)
(2) JWH-015 ((2-IVIethyl-l-propyl- lH-indol-3-yl)-l-naphthalenylmethanone)
(3) JWH-018(l-pentyl-3-(l-naphthoyl) indole)
(4) JWH-019 (l-hexyl-3-(naphthalen-l-oyl) indole)
(5) JWH-073 (naphthalen-l-yt- (l-butylindol-3-yl)methanone)
(6) JWH-081 (4-methoxynaphthalen-l-yl- (l-pentylindol-3-yl)methanone)
(7) JWH-098 (4-methoxynaphthalen-l-yl- (l-pentyl-2-methylindol-3-yl)methanone)
(8) JWH-122(l-Pentyl-3-(4-methyl -l-naphthoyl)indole)
(9) JWH-164 (7-methoxynaphthalen-l-yl- (l-pentylindol-3-yl)methanone
(10) JWH-200 (l-(2-morpholin- 4-ylethyl) indol-3-yl)-naphthalen-l-ylmethanone)
(11) JWH-203 (2-(2-chlorophenyl)-1- (l-pentylindol-3-yl)ethanone
(12) JWH-210 (4-ethylnaphthalen-l-yl- (l-pentylindol-3-yl)methanone
(13) JWH-250 (l-pentyl-3- (2-methoxyphenylacetyl)indole)
(14) JWH-251 (l-pentyl-3- (2-methylphenylacetyl)indole)
(15) JWH-398 (l-pentyl-3- (4-chloro-l-naphthoyl) indole)
(16) HU-210 ((6aR,10aR)-9- (Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2- yl)-6a,7,10,10a-tetrahydrobenzo [c]chromen-l-ol)
(17) HU-211 ((6aS,10aS)- 9-(Hydroxymethyl) -6,6-dimethyl- 3- (2-methyloctan-2 -yl)-6a,7,10, 10a-tetrahydrobenzo [c]chromen-l-ol)
(18) HU-308 ([lR,2R,5R)-2- [2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-di methyl-4-bicyclo[3.1.1]hept-3-enyl] methanol)
(19) HU-331 ((3-hydroxy-2- [(lR,6R)-3- methyl-6-(l-methylethenyl)-2-cyclohexen-l-yl]-5- pentyl-2,5-cyclohexadiene-l,4-dione)
(20) CP 55,940 (2-[(lR,2R,5R) -5-hydroxy -2- (3-hydroxypropyl) cyclohexyl]- 5- (2-methyloctan-2-yl)phenoI)
(21) CP 47,497 (2-[(lR,3S)-3- hydroxycyclohexyl]- 5- (2-methyloctan-2-yl)phenol) and its homologues
(22) WIN 55,212-2 ((R)-(+)-[2,3- Dihydro-5 -methyl-3- (4-morpholinylmethyl)pyrrolo [1,2,3-de)-l,4-benzoxazin-6-yl]-l- nepthalenylmethanone)
(23) RCS-4 ((4-methoxyphenyl)(l-pentyl -lH-indol-3-yl)methanone)
(24) RCS-8 (l-(l-(2-cyclohexylethyl) -lH-indol-3-yl)-2-(2-methoxyphenyl)ethanone).
SYNTHETIC PSYCHEDELIC/ HALLUCINOGEN. Any compound that mimics the effects of any federally controlled Schedule I substance, including but not limited to, any quantity of a natural or synthetic material, compound, mixture, preparation, substance and their analog (including salts, isomers, esters, ethers and salts of isomers) containing substances which have a psychedelic/hallucinogenic effect on the central nervous system and/or brain, such as:
(1) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E);
(2) 2-(2,5-dimethoxy-4-methylphenyl) ethanamine (2C-D);
(3) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C);
(4) 2-(4-lodo-2,5-dimethoxyphenyl) ethanamine (2C-I);
(5) 2-(4-(Ethylthio)-2,5-dimethoxyphenyl) ethanamine (2C-T-2);
(6) 2-(4-(lsopropylthio)-2,5- dimethoxyphenyl)ethanamine (2C-T-4);
(7) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
(8) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N);
(9) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P).
SYNTHETIC STIMULANT. Any compound that mimics the effects of any federally controlled Schedule I substance such as cathinone, methcathinone, MDMA and MDEA, including, but
not limited to, any quantity of a natural or synthetic material, compound, mixture, preparation, substance and their analog (including salts, isomers, and salts of isomers) containing substances which have a stimulant effect on the central nervous system, such as:
(1) 3-Fluoromethcathinone
(2) 4-Fluoromethcathinone (other name: flephedrone)
(3) 3,4-Methylenedioxymethcathinone (other name: methylone, MDMC)
(4) 3,4-Methylenedioxypyrovalerone (other name: MDPV)
(5) 4-Methylmethcathinon (other names: mephedrone, 4-MMC)
(6) 4-Methoxymethcathinone (other names: methedrone, bk-PMMA, PMMC)
(7) 4-Ethylmethcathinone (other name: 4-EMC)
(8) Ethcathinone
(9) Beta-keto-–methylbenzodioxyolylpropyl amine (other names: butylone, bk-MBDB)
(10) Napthylpyrovalerone (other names: naphyrone, NRG-1)
(11) N,N-dimethylcathinone (other name: metamfepramone)
(12) Alpha-pyrrolidinopropiophenone (other name: alpha-PPP)
(13) 4-methoxy-alpha-pyrrolidinopropio phenone (other name: MOPPP)
(14) 3,4-methylenedioxy-alpha- pyrrolidinopropiophenone (other name: MDPPP)
(15) Alpha-pyrrolidinovalerophenone (other name: alpha-PVP)
(16) 6,7-kihydro-5H-indeno(5,6-d)-l,3- dioxal-6-amine) (other name: MDAI)
(17) Any compound that is structurally derived from 2-amino-1-phenyl-1-propanone by modification or substitution in any of the following ways:
(a) In the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
(b) At the 3-position with an alkyl substituent;
(c) At the nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups; or
(d) By inclusion of the nitrogen atom in a cyclic structure.
(Ord. 2011-62, passed 12-19-11)